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The Target Temperature Management (TTM) Trial ran-
domized 950 unconscious, adult patients with return of
spontaneous circulation after out-of-hospital cardiac
arrest (CA) of presumed cardiac cause to strict tempera-
ture management at either 33°C or 36°C. Temperature
was managed with intravascular or surface cooling
devices for 36 hours, while the patients were sedated and
mechanically ventilated. Prognostication and decisions
on life-sustaining treatments were postponed until 4.5 to
5 days after CA in the general case [1]. There was no dif-
ference in the primary outcome: survival until the end of
the trial (mortality 50% in the 33°C group and 48% in the
36°C group, hazard ratio 1.06, 95% confidence interval
0.89 to 1.28, p = 0.51) or the secondary outcomes: neuro-
logical function at 6 months and adverse events [2]. In a
substudy with detailed cognitive assessment, the groups
were similar [3].
The TTM Trial has been criticized for imbalances
between groups, the long time to reaching target tem-
perature, poor temperature control, the short time to
basic cardiopulmonary resuscitation and that wide inclu-
sion criteria might have missed subgroups with potential
benefit of the lower temperature. Regarding baseline dif-
ferences, the adjusted analyses moved the point estimate
of the intervention in direction benefit for the 36°C
group (hazard ratio 1.14, p = 0.18) [2]. The time to reach
a temperature below 34°C was similar to large registries
[4] and faster than the most influential previous rando-
mized trial [5]. Temperature depicted with ±2 standard
deviations will visually give an impression of imprecision,
compared with studies reporting the interquartile range
[5]. Time to basic life support was reported for the sub-
groups of patients having bystander cardiopulmonary
resuscitation only and was identical to previous reports
[6]. Subgroup analyses did not show signals in favor of
any of the temperatures, but may suggest potential harm
of 33°C in circulatory unstable patients [7].
In summary, the results of the TTM Trial are generaliz-
able to the majority of patients admitted to intensive care
after a CA of a presumed cardiac cause and temperature
management at either 33°C or 36°C after CA should be
regarded as evidence-based medicine. Taking the confi-
dence limits of the TTM Trial primary outcome into
account, comprising potential clinically significant benefit
of both 33°C and 36°C arms, future randomized trials of
intensive care treated CA patients must be large and form-
ing international networks will be imperative to move the
field forward. The TTM Trial highlights that we still do
not have the final answer as to how to best manage tem-
perature after CA and that many questions about efficacy
and effectiveness remain open.
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